Detection of squamous cell carcinoma antigen with two systems in the follow-up of patients with cervical cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Since squamous cell carcinoma antigen (SCC-Ag) testing became commercially available on the Architect platform, the previously established method on the Abbott IMx platform has been progressively replaced. Aim of this work was to compare SCC-Ag values obtained with the 2 methods. Clinical and laboratory data of 188 patients for whom SCC-Ag determination was requested, were reviewed. IMx was used to determine the levels of SCC-Ag from June 2007 to May 2009, while the Architect system was used from June 2009 to April 2011. Only patients consistently diagnosed with no evidence of disease, for whom at least 2 determinations with each analyzer were available were used. Comparison of the results obtained with the 2 systems was then performed. Mean values for SCC-Ag were 0.56 ng/mL (Standard Error (SE): 0.08) with the IMx method, and 1.08 ng/mL (SE 0.10) with Architect (p

Original languageEnglish
Pages (from-to)313-317
Number of pages5
JournalInternational Journal of Biological Markers
Volume28
Issue number3
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Cervical cancer
  • Methods comparison
  • Squamous cell carcinoma antigen
  • Tumor markers

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Detection of squamous cell carcinoma antigen with two systems in the follow-up of patients with cervical cancer'. Together they form a unique fingerprint.

Cite this